The present invention relates to stable liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.

The present invention relates to granulates of Dimethyl fumarate comprising of gastro resistant or enteric polymers and other excipients. The invention also relates to novel oral dosage forms of Dimethyl fumarate comprising an admixture of Dimethyl fumarate and excipients filled in an enteric coated capsule. ...

Novel Compositions of Carfilzomib Abstract The invention relates to novel parenteral compositions of Carfilzomib or its pharmaceutically acceptable salts, solvates and hydrates thereof. More specifically, the invention relates to cyciodextrin free lyophilized formulations of Carfilzomib.

Stable, ready to use Cyclophosphamide liquid formulations The present invention relates . to stable ready to use liquid formulations of Cyclophosphamide for parenteral use. The ready to use composition comprises Cyclophosphamide dissolved in a solvent system comprising a solvent, cosolvent(s) and antioxidant(s). ...

The present invention relates to novel solvate forms of cabazitaxel and preparation thereof. The invention further relates to tertiary-butyl alcohol solvate form of Cabazitaxel, and process of preparation thereof, and pharmaceutical compositions comprising of the novel solvate form of cabazitaxel. ...

STABLE LIQUID PHARMACEUTICAL COMPOSITIONS OF BORTEZOMIB Abstract The present invention relates to stable ready to use liquid pharmaceutical formulations of Bortezomib or a pharmaceutically acceptable salt thereof. Further the present invention relates to pharmaceutical composition of Bortezomib comprising a solven...

The present invention relates to stable liquid pharmaceutical formulation of Bendamustine or a pharmaceutically acceptable salt thereof; wherein the formulation is devoid of propylene glycol.

Abstract The present invention relates to novel compositions of long acting Aripiprazole and its pharmaceutically acceptable salts, solvates, hydrates, polymorphs thereof in nonlyophilizeid form. Further the present application is related to the"methods of preparing Aripiprazole compOsitions. The present inventi...

Abstract Glycol free stable liquid compositions of Bendamustine The present invention relates to ready to use stable liquid pharmaceutical formulations of Bendamustine or a pharmaceutically acceptable salt thereof; wherein the formulation is devoid of glycols. Further the present invention relates to pharmaceu...

The present invention provides a stable ready to use liquid parenteral formulations of Pemetrexed or a pharmaceutically acceptable salt thereof. Further this invention also describes process of preparing such formulations.

Abstract Stabilized liquid formulation of Levothyroxine The present invention relates to stabilized liquid formulations of Levothyroxine or a pharmaceutically acceptable salt thereof, intended for parenteral administration. Further this invention.also describes process of preparing such compositions. ...

The present invention relate to stable oral pharmaceutical formulations of Abiraterone comprising of Abiraterone, solubilizing agents and other pharmaceutically acceptable excipients, and method of preparing such formulations.

The present invention relates to stable pharmaceutical formulations of Teriflunomide tablets comprising of Teriflunomide, colloidal silicon dioxide and other pharmaceutically acceptable excipients. Further the invention relates to method of preparing Teriflunomide tablets.

The present invention relates to parenteral pharmaceutical formulation of Regadenoson comprising of Regadenoson, one or more cyclodextrins and pharmaceutically acceptable excipients.

The present invention relates to stable parenteral pharmaceutical formulation of Posaconazole having a pH from about 4 to 8. Further the invention also provides method of preparing such formulation.

The present invention relates to a process for preparing a liquid parenteral formulation of Gadoterate meglumine which is used as a contrast agent for magnetic resonance imaging.

The present invention provides a stable ready to use liquid parenteral formulations of Pemetrexed or a pharmaceutically acceptable salt thereof. Further this invention also describes process of preparing such formulations.

The present invention relates to novel oral spray formulations of Levothyroxine. Further the invention also describes process for preparing such formulations.

The present invention relates to novel co-crystal forms of Agomelatine, process of preparation and solid oral pharmaceutical formulations containing them.

The present invention relates to novel pharmaceutical compositions of Regadenoson and its pharmaceutically acceptable salts, solvates or hydrates in the form of solution, wherein the compositions are free from phosphate buffer and EDTA. Further the invention relates to pharmaceutical composition of Regadenoson compr...

The present invention relates to liquid formulations of Fosaprepitant intended for parenteral administration. Further this invention also describes process for preparing such formulations.

The present invention relates to stable lyophilized parenteral formulation of Carfilzomib. Further the invention also describes process of preparing such formulations.

The present invention provides stable parenteral formulations of Melphalan or a pharmaceutically acceptable salt thereof. Further this invention also describes process of preparing such compositions.

The present invention relates to stable liquid parenteral formulations of Palonosetron intended for subcutaneous administration. The invention further describes process of preparing such formulations.

The present invention relates to parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid. The present invention also relates to process of preparing such formulations.

ORAL LIQUID FORMULATIONS OF ABIRATERONE Abstract The present invention relates to liquid formulations of Abiraterone intended for oral administration. The invention provides suspension and emulsion formulations of Abiraterone and process of preparing such formulations. Further, the invention relates to Nanoemulsio...

The present invention relates to a stable, alcohol-free formulations of indocyanine green. These indocyanine green formulations are lyophilized and further comprise of indocyanine green and other optional excipients that are stable up to 24hrs even after reconstitution with diluent solution. Further, the present inv...

Enclosed

Enclosed

Enclosed

The present invention relates to novel parenteral formulations of vasopressin, comprising of vasopressin, stabilizers, solvent and other pharmaceutically acceptable excipients.